COVID-19 is the public health emergency that dominates the headlines, but it isn’t the only one. The opioid epidemic was raging for several years before COVID and is still going strong. Despite numerous years spent addressing the problem, this public health crisis is now worse than ever.
This widespread and often deadly addiction may also share something else with COVID: a vaccine may soon be used to treat it.
What makes this trial special is that many failed attempts have preceded it. Hopes for an opioid vaccine have been around since the 1970s, although trials until recently have fallen short. Most never made it out of the discovery phase.
But support for the idea has persisted. A 2019 U.S. Government Accountability Office (GAO) report discussing opioid vaccines notes at least three early-stage clinical trials then in development, including one from the Walter Reed Army Institute of Research testing a heroin vaccine. In August 2020, The National Institute of Allergies and Infectious Diseases began funding these projects.
Hopes remain high that an approved opioid vaccine lies just around the corner. However, one of the limitations involved in this strategy is the specificity built into each shot. The one now in human trials, for example, only blocks oxycodone molecules. It doesn’t interfere with other opioids, such as fentanyl or heroin. Proponents of these vaccines say this feature is a benefit, because it leaves the door open for other treatment options in the event a patient might require pain management in the future. However, it also means that multiple vaccines are necessary if patients turn to other opioids when they can no longer get a fix from their favorite.
And there’s a wide spectrum of choices when it comes to opioids, which originated from the opium poppy—a plant at the center of two major wars between Great Britain and China in the 1800s. Since then, the humble poppy has spawned many opium derivatives that are stronger and far more addictive, including OxyContin, morphine, and heroin.
Due to fentanyl’s capacity to kill, and the enormous quantities that have been smuggled across the U.S. borders in recent years from China and Mexico, some believe it must be taken more seriously. In July, FAF sent a letter to President Joe Biden, urging him to classify fentanyls as weapons of mass destruction.
Vaccines for Every Ill
An opioid vaccine may sound strange, because we typically think of vaccines as treatments that provide protection against contagious diseases. But the injection format has expanded to address a range of issues. Vaccines are now in development to fight Alzheimer’s, Parkinson’s, heart disease, allergies, autoimmune disease, and more.In fact, two companies currently known for creating vaccines for COVID—BioNTech and Moderna—were originally set up to develop vaccines to fight cancer.
Vaccination has been around for more than 200 years, but today, it’s more popular than ever. From the constant messaging urging everyone to get their COVID shot and follow-up boosters, to the slightly less persistent messages to get flu, shingles, and other shots available at your local drug store.
But will a shot solve the opioid crisis? It isn’t likely. Even the most ardent supporters of the treatment admit it’s no magic bullet. If and when an opioid jab does finally make it to market, it’s at best expected to fill a few gaps left by the other three medications to treat opioid abuse that are already approved by the U.S. Food and Drug Administration: methadone, buprenorphine, and naltrexone. Ideally, the shot would provide some preventative protection when drugs to address overdoses aren’t readily available.
According to the GAO, the protection of a single shot could perhaps last months or even years, and would require little medical supervision.
One question about what the regulatory framework will be for any opioid vaccine that does get approved, since vaccine makers currently enjoy unique protection from financial liability for vaccine injury claims. While a drug maker can be sued and subjected to a class action lawsuit for problems associated with their products, in the United States vaccine makers can’t, due to the National Childhood Vaccine Injury Act passed in 1986 and more recent legislation approved in response to COVID-19.